NeuroPace Stock Price, News & Analysis (NASDAQ:NPCE) $8.31 +0.18 (+2.21%) (As of 12/5/2023 ET) Add Compare Share Share Today's Range$7.69▼$8.4150-Day Range$5.90▼$9.7352-Week Range$1.22▼$9.73Volume63,265 shsAverage Volume45,133 shsMarket Capitalization$218.42 millionP/E RatioN/ADividend YieldN/APrice Target$9.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media NeuroPace MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside15.5% Upside$9.60 Price TargetShort InterestHealthy1.40% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.15Based on 5 Articles This WeekInsider TradingSelling Shares$191,658 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.38) to ($1.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.16 out of 5 starsMedical Sector345th out of 948 stocksSurgical & Medical Instruments Industry36th out of 82 stocks 2.3 Analyst's Opinion Consensus RatingNeuroPace has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.60, NeuroPace has a forecasted upside of 15.5% from its current price of $8.31.Amount of Analyst CoverageNeuroPace has only been the subject of 4 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.40% of the float of NeuroPace has been sold short.Short Interest Ratio / Days to CoverNeuroPace has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroPace has recently decreased by 61.83%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeuroPace does not currently pay a dividend.Dividend GrowthNeuroPace does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NPCE. Previous Next 2.1 News and Social Media Coverage News SentimentNeuroPace has a news sentiment score of -0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for NeuroPace this week, compared to 1 article on an average week.Search Interest1 people have searched for NPCE on MarketBeat in the last 30 days. MarketBeat Follows1 people have added NeuroPace to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeuroPace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $191,658.00 in company stock.Percentage Held by Insiders27.50% of the stock of NeuroPace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.69% of the stock of NeuroPace is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NeuroPace are expected to grow in the coming year, from ($1.38) to ($1.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuroPace is -5.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuroPace is -5.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuroPace has a P/B Ratio of 5.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NeuroPace Stock (NASDAQ:NPCE)NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.Read More NPCE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NPCE Stock News HeadlinesDecember 5, 2023 | americanbankingnews.comNeuroPace (NASDAQ:NPCE) Price Target Raised to $9.00 at Morgan StanleyDecember 1, 2023 | finance.yahoo.comNeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual MeetingDecember 6, 2023 | Financial Alphas (Ad)Countries Are Investing Heavily Into Securing Energy IndependenceThere's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.November 21, 2023 | finance.yahoo.comNeuroPace to Present at the Piper Sandler 35th Annual Healthcare ConferenceNovember 11, 2023 | msn.comCantor Fitzgerald Initiates Coverage of NeuroPace (NPCE) with Overweight RecommendationNovember 10, 2023 | markets.businessinsider.comEpilepsy-Focused MedTech NeuroPace Has Attractive Entry Point, Competitive PositionNovember 7, 2023 | finance.yahoo.comNeuroPace, Inc. (NASDAQ:NPCE) Q3 2023 Earnings Call TranscriptNovember 7, 2023 | finanznachrichten.deNeuroPace, Inc.: NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue GuidanceDecember 6, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 6, 2023 | msn.comNeuroPace GAAP EPS of -$0.28 beats by $0.13, revenue of $16.4M beats by $2.18MNovember 6, 2023 | finance.yahoo.comNeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue GuidanceNovember 6, 2023 | finance.yahoo.comNeuroPace Inc (NPCE) Reports 47% YoY Revenue Growth in Q3 2023, Raises Full Year Revenue GuidanceNovember 2, 2023 | finance.yahoo.comNeuroPace, Inc.'s (NASDAQ:NPCE) top owners are private equity firms with 54% stake, while 21% is held by institutionsOctober 18, 2023 | finanznachrichten.deNeuroPace, Inc.: NeuroPace Announces RNS System Enhancements Designed to Streamline CareOctober 17, 2023 | finance.yahoo.comNeuroPace Announces RNS System Enhancements Designed to Streamline CareOctober 16, 2023 | finance.yahoo.comNeuroPace to Report Third Quarter 2023 Financial Results on November 6, 2023October 5, 2023 | benzinga.comNeuroPace 10% Owner Trades $75K In Company StockOctober 5, 2023 | finance.yahoo.comOrbiMed Advisors LLC Reduces Stake in NeuroPace IncSeptember 20, 2023 | finance.yahoo.comNeuroPace to Participate in 2023 Cantor Fitzgerald Global Healthcare ConferenceAugust 25, 2023 | msn.comMorgan Stanley Upgrades NeuroPace (NPCE)August 24, 2023 | finance.yahoo.comNeuroPace to Participate in Upcoming Investor ConferencesAugust 13, 2023 | finance.yahoo.comRainbows and Unicorns: NeuroPace, Inc. (NASDAQ:NPCE) Analysts Just Became A Lot More OptimisticAugust 9, 2023 | finanznachrichten.deNeuroPace, Inc.: NeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue GuidanceAugust 8, 2023 | finance.yahoo.comNeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue GuidanceJuly 19, 2023 | finance.yahoo.comNeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock MarketJuly 18, 2023 | finance.yahoo.comNeuroPace to Report Second Quarter 2023 Financial Results on August 8, 2023June 29, 2023 | finanznachrichten.deNeuroPace, Inc.: NeuroPace Announces CEO TransitionSee More Headlines Receive NPCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NPCE CUSIPN/A CIK1528287 Webwww.neuropace.com Phone650-237-2700FaxN/AEmployees169Year FoundedN/APrice Target and Rating Average Stock Price Target$9.60 High Stock Price Target$11.00 Low Stock Price Target$9.00 Potential Upside/Downside+15.5%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,080,000.00 Net Margins-62.96% Pretax Margin-62.96% Return on Equity-151.83% Return on Assets-35.93% Debt Debt-to-Equity Ratio3.42 Current Ratio6.55 Quick Ratio5.79 Sales & Book Value Annual Sales$60.20 million Price / Sales3.63 Cash FlowN/A Price / Cash FlowN/A Book Value$1.40 per share Price / Book5.94Miscellaneous Outstanding Shares26,284,000Free Float19,056,000Market Cap$218.42 million OptionableNot Optionable Beta2.13 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMs. Irina Ridley (Age 37)Chief Legal Officer & Corporate Secretary Comp: $499.31kDr. Martha J. Morrell (Age 66)Chief Medical Officer Comp: $555.87kMr. Joel D. Becker (Age 55)CEO & Director Ms. Rebecca L. Kuhn (Age 62)CFO, VP of Finance & Administration and Assistant Secretary Comp: $440.92kMs. Kelley NicholasVice President of SalesMs. Irene Thomas (Age 54)Vice President of Human Resources More ExecutivesKey CompetitorsAlpha Tau MedicalNASDAQ:DRTSProfound MedicalNASDAQ:PROFQuipt Home MedicalNASDAQ:QIPTLyra TherapeuticsNASDAQ:LYRAOrchestra BioMedNASDAQ:OBIOView All CompetitorsInsiders & InstitutionsLtd. KckSold 7,282 sharesTotal: $64,372.88 ($8.84/share)Ltd. KckSold 6,490 sharesTotal: $58,150.40 ($8.96/share)Morgan StanleyBought 40,850 shares on 11/16/2023Ownership: 9.130%Kent Lake Capital LLCBought 425,212 shares on 11/15/2023Ownership: 2.186%FMR LLCSold 517,418 shares on 11/13/2023Ownership: 2.687%View All Insider TransactionsView All Institutional Transactions NPCE Stock Analysis - Frequently Asked Questions Should I buy or sell NeuroPace stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeuroPace in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NPCE shares. View NPCE analyst ratings or view top-rated stocks. What is NeuroPace's stock price target for 2024? 5 brokerages have issued 12 month price objectives for NeuroPace's shares. Their NPCE share price targets range from $9.00 to $11.00. On average, they expect the company's share price to reach $9.60 in the next year. This suggests a possible upside of 15.5% from the stock's current price. View analysts price targets for NPCE or view top-rated stocks among Wall Street analysts. How have NPCE shares performed in 2023? NeuroPace's stock was trading at $1.49 at the start of the year. Since then, NPCE stock has increased by 457.7% and is now trading at $8.31. View the best growth stocks for 2023 here. Are investors shorting NeuroPace? NeuroPace saw a decrease in short interest in November. As of November 15th, there was short interest totaling 151,000 shares, a decrease of 61.8% from the October 31st total of 395,600 shares. Based on an average daily trading volume, of 69,000 shares, the days-to-cover ratio is presently 2.2 days. Approximately 1.4% of the company's shares are sold short. View NeuroPace's Short Interest. When is NeuroPace's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024. View our NPCE earnings forecast. How were NeuroPace's earnings last quarter? NeuroPace, Inc. (NASDAQ:NPCE) announced its quarterly earnings results on Monday, November, 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.11. The firm earned $16.43 million during the quarter, compared to analyst estimates of $14.23 million. NeuroPace had a negative net margin of 62.96% and a negative trailing twelve-month return on equity of 151.83%. When did NeuroPace IPO? (NPCE) raised $85 million in an initial public offering (IPO) on Thursday, April 22nd 2021. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers. Who are NeuroPace's major shareholders? NeuroPace's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Morgan Stanley (9.13%), FMR LLC (2.69%), Kent Lake Capital LLC (2.19%), EAM Investors LLC (0.54%), Barclays PLC (0.04%) and Citigroup Inc. (0.01%). Insiders that own company stock include Accelmed Partners Ii LP, Frank M Fischer, Irina Ridley, Ltd Kck and Orbimed Advisors Llc. View institutional ownership trends. How do I buy shares of NeuroPace? Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:NPCE) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.